United States - English - NLM (National Library of Medicine)

azurity pharmaceuticals, inc. - triptorelin (unii: 9081y98w2v) (triptorelin - unii:9081y98w2v) - triptorelin 22.5 mg in 2 ml - triptodur is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (cpp). - hypersensitivity: triptodur is contraindicated in individuals with a known hypersensitivity to triptorelin, any other component of the product, or other gnrh agonists or gnrh [see adverse reactions (6.2)] . - pregnancy: triptodur may cause fetal harm [see use in specific populations (8.1)] . risk summary triptodur is contraindicated in women who are pregnant [see contraindications (4)] since expected hormonal changes that occur with triptodur treatment increase the risk for pregnancy loss. available data with triptorelin use in pregnant women are insufficient to determine a drug-associated risk of adverse developmental outcomes. based on mechanism of action in humans and findings of increased pregnancy loss in animal studies, triptodur may cause fetal harm when administered to pregnant women. advise pregnant women of the potential risk to a fetus. the estimated background risk of m

Ireland - English - HPRA (Health Products Regulatory Authority)

ferring ireland ltd - triptorelin - powder and solvent for suspension for injection - 3.75 milligram(s) - gonadotropin releasing hormone analogues; triptorelin

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - triptorelin acetate 4mg equivalent to 3.75 mg triptorelin;   - solution for injection - 3.75 mg - active: triptorelin acetate 4mg equivalent to 3.75 mg triptorelin   excipient: polyglactin carmellose sodium polysorbate 80 water for injection

Israel - English - Ministry of Health

medison pharma ltd - triptorelin as acetate - powder and solvent for suspension for injection - triptorelin as acetate 3.75 mg/vial - triptorelin - triptorelin - prostate cancer: treatment of prostate cancer with metastases. patients who have not previously received hormone therapy show a more marked response to the treatment and respond more frequently if the patient has not previously receieved another hormone treatment. precocious puberty: (before 8 years in girls and 10 years in boys). genital and extragenital endometriosis (stage i to stage iv): treatment should not be administered for more than 6 months. it is not recomended to start a second treatment course with triptorelin or another gnrh analogue. treatment of uterine fibromyomas prior to surgery: associated with anaemia ( haemoglobin less than, or equal to 8 g/dl). when a reduction in the size of the fibromyoma is necessary to facilitate or modify the surgical technique: endoscopic surgery, transvaginal surgery. the treatment duration is restricted to 3 months. female infertility: supplementary treatment in combination with gonadotrophins (hmg, fsh, hcg) to induce ovulation with a view to in vitro fertilisa

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 31 mg (equivalent: triptorelin, qty 22.5 mg) - suspension, powder for - excipient ingredients: polyglactin; carmellose sodium; polysorbate 80; mannitol - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.,diphereline 22.5mg 6 month formulation only:,diphereline 22.5 mg is indicated for the treatment of children 2 years and older with central precocious puberty (cpp).

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 19.32 mg - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 5.6 mg (equivalent: triptorelin, qty 3.75 mg) - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

Malta - English - Medicines Authority

ferring spa via senigallia 18/2, milan, italy - triptorelin - solution for injection - triptorelin 2 mg - endocrine therapy

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as embonate - powder and solvent for suspension for injection - triptorelin as embonate 22.5 mg - triptorelin - symptomatic treatment of advanced hormone-dependent prostate cancer. as an alternative treatment, if orchiectomy or the administration of oestrogens are not indicated or are unacceptable to the patient. treatment of central precocious puberty (cpp) in children 2 years and older with an onset of cpp before 8 years in girls and 10 years in boys.

Canada - English - Health Canada

vetoquinol n a inc - triptorelin (triptorelin acetate) - gel - 100mcg - triptorelin (triptorelin acetate) 100mcg - swine (pigs)